File: '\\swfile\EmailIn\20260227 164837 Attachment BioNxt - News Release announcing Option grants hr.docx'

LEGAL_48958362.4

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BIONXT SOLUTIONS ANNOUNCES INVESTOR RELATIONS AGREEMENTS

AND OPTION GRANTS

Vancouver, Canada (February 27, 2026) - BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT / OTC: XPHYF / FSE: 4XT) announces that it has entered into agreements with certain investment relations service providers and granted an aggregate of 5,150,000 stock options ("Options") to insiders, employees, consultants and investor relations service providers of the Company, pursuant to the Company's stock option plan (the "Option Plan").

On February 27, 2026, the Company entered into an agreement with Clay McMeekin ("McMeekin) of Victoria, British Columbia, pursuant to which McMeekin will provide to the Company certain investor relations services, including but not limited to targeting institutional investors (pension funds, hedge funds, family offices) and qualified retail (individual) investors. Under the terms of the agreement, McMeekin will provide the services from February 27, 2026, until August 31, 2026. In consideration of the services, will grant McMeekin 1,000,000 Options, each entitling McMeekin to acquire one Common Share at an exercise price of $0.63 per Common Share for a period of two years, in accordance with the Option Plan. 25% of the Options granted to McMeekin will vest every three months following the date of grant until the date that is 12 months following the date of grant.

On February 27, 2026, the Company also formalized the renewal of its agreement dated August 22, 2025, with Cayo Ventures GmbH ("Cayo"), wholly owned by Yves Toelderer ("Toelderer") of Zug, Switzerland, pursuant to which Cayo will provide to the Company certain investor relations services, including but not limited to, German language video interviews, opt-in email news distribution, and digital marketing services. Services will be provided in Europe until June 30, 2026, with services and compensation up to a total of 30,000 Euros per week depending on success as measured via observed trading activity in Europe. Additionally, the Company granted to Yves Toelderer, principal of Cayo, 250,000 Options, each entitling Mr. Toelderer to acquire one Common Share at an exercise price of $0.63 per Common Share for a period of two years, in accordance with the Option Plan. 25% of the Options granted to Mr. Toelderer will vest every three months following the date of grant until the date 12 months following the date of grant.

Additionally, the Company granted 3,800,000 Options, each entitling the holder thereof to acquire one common share in the capital of the Company (a "Common Share") at an exercise price of $0.63 per Common Share for a period of five years, to certain insiders, consultants and an employee of the Company and all such Options vested immediately. The Company also granted 100,000 Options, each entitling the holder thereof to acquire on Common Share at an exercise price of $0.63 per Common Share for a period of two years, to certain consultants of the Company. All such Options vested immediately.

The Option Plan was last approved by the shareholders of the Company on November 7, 2025.

The Options and any underlying common shares in the capital of the Company will be subject to a four month and one day hold period pursuant to the policies of the Canadian Securities Exchange.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co-Founder, CEO and Director

Email: investor.relations@bionxt.com

Phone: +1 780-818-6422

Web: www.bionxt.com

LinkedIn: https://www.linkedin.com/company/bionxt-solutions

Instagram: https://www.instagram.com/bionxt